WSJ News Exclusive | Ecstasy-for-Medicine Advocate MAPS Looks for Cash Lifeline

[ad_1]

MAPS, a nonprofit, is working on an $85 million private share sale to keep itself afloat until mid-2024, when it hopes to start selling MDMA in the U.S.

[ad_2]

Source link